-
公开(公告)号：KR1020100097526A
公开(公告)日：2010-09-03
申请号：KR1020090016511
申请日：2009-02-26
Applicant: 전남대학교산학협력단
IPC: C07K16/18 , A61K39/395
Abstract: PURPOSE: A peptide antigen with enhanced immunogenicity and a method for producing the same are provided to enhance immunogenicity and to increase antibody production efficiency. CONSTITUTION: A peptide antigen with enhanced immunogenicity comprises an amino acid sequence with two or more tandem repeat amino acid sequence unit. The peptide antigen additionally contains proline between amino acid sequence units. A vaccine composition contains the peptide antigen, nucleic acid encoding the same, or antibody to the peptide antigen. A method for producing the peptide antigen with immunogenicity comprises: a step of determining amino acid sequence corresponding to an epitope of a target antigen; and a step of preparing a polypeptide comprising two or more tandem repeat amino acid sequence units; or a step of preparing amino acid sequence which additionally contains proline.
Abstract translation: 目的：提供具有增强的免疫原性的肽抗原及其制备方法，以增强免疫原性并提高抗体生产效率。 构成：具有增强的免疫原性的肽抗原包含具有两个或多个串联重复氨基酸序列单元的氨基酸序列。 肽抗原在氨基酸序列单元之间另外含有脯氨酸。 疫苗组合物含有肽抗原，编码其的核酸或针对肽抗原的抗体。 用于产生具有免疫原性的肽抗原的方法包括：确定对应于靶抗原表位的氨基酸序列的步骤; 以及制备包含两个或多个串联重复氨基酸序列单元的多肽的步骤; 或另外含有脯氨酸的氨基酸序列的制备工序。
-
公开(公告)号：KR1020100096489A
公开(公告)日：2010-09-02
申请号：KR1020090015390
申请日：2009-02-24
Applicant: 전남대학교산학협력단
CPC classification number: A61K38/20 , C07K14/54 , C12N15/63 , Y10S514/824
Abstract: PURPOSE: A pharmaceutical composition containing interleukin, interleukin-24 agonist or gene encoding interleukin-24 is provided to treat or prevent hypertension or hypertension complication by suppressing expression of hypertension-associated gene. CONSTITUTION: A composition for preventing or treating hypertension contains interleukin-24, interleukin-24 agonist, gene encoding interleukin-24, mutant, or complement thereof. A gene encoding interleukin-24 is contained in viral or non-viral transporter. The composition additionally contains other material for treating hypertension.
Abstract translation: 目的：提供含有白介素，白细胞介素-24激动剂或编码白介素24的基因的药物组合物，通过抑制高血压相关基因的表达来治疗或预防高血压或高血压并发症。 构成：用于预防或治疗高血压的组合物含有白细胞介素-24，白细胞介素-24激动剂，编码白细胞介素-24，突变体或其补体的基因。 编码白细胞介素-24的基因包含在病毒或非病毒转运蛋白中。 该组合物另外含有用于治疗高血压的其它材料。
-
公开(公告)号：KR102226873B1
公开(公告)日：2021-03-11
申请号：KR1020190067241
申请日：2019-06-07
Applicant: 전남대학교산학협력단
IPC: C07D309/30 , C12P17/06
Abstract: 본발명의일 실시예는하기화학식 1로표시되는스타틴계화합물인 6'-하이드록시메틸-모나콜린 J(6'-hydroxymethyl-monacolin J) 및이의제조방법을제공한다: [화학식 1] JPEG112019058262388-pat00004.jpg4044
-
公开(公告)号：KR1020200140530A
公开(公告)日：2020-12-16
申请号：KR1020190067241
申请日：2019-06-07
Applicant: 전남대학교산학협력단
IPC: C07D309/30 , C12P17/06
Abstract: 본발명의일 실시예는하기화학식 1로표시되는스타틴계화합물인 6'-하이드록시메틸-모나콜린 J(6'-hydroxymethyl-monacolin J) 및이의제조방법을제공한다: [화학식 1] JPEGpat00004.jpg4044
-
公开(公告)号：KR101958346B1
公开(公告)日：2019-03-15
申请号：KR1020170136365
申请日：2017-10-20
Applicant: 전남대학교산학협력단
IPC: C07D471/04 , A61K31/437
-
Patent Agency Ranking16.发明公开박테리아 시토크롬 Ｐ450을 이용한 플루바스타틴으로부터 대사산물의 신규한 생산방법 및 이를 위한 조성물 有权使用细菌细胞色素P450的FLUVASTATIN代谢物的新型制备方法及其组合物
公开(公告)号：KR1020140122697A
公开(公告)日：2014-10-20
申请号：KR1020140111204
申请日：2014-08-26
Applicant: 전남대학교산학협력단
IPC: C12N9/02 , C07K14/195 , C12P1/04 , C12Q1/26
CPC classification number: C12N9/0042 , C12N9/0006 , C12N9/0071 , C12P17/10 , C12Y101/01049 , C12Y106/02004 , C12Y114/14001
Abstract: 본발명은박테리아시토크롬 P450을이용한플루바스타틴으로부터대사산물의신규한생산방법및 이를위한조성물에관한것으로, 보다상세하게는박테리아시토크롬 P450 BM3(CYP102A1), CYP102A1의돌연변이체(mutant) 및 CYP102A1의돌연변이체의카메라(chimera)를포함하는플루바스타틴으로부터 5-히드록실산물및 6-히드록실산물제조용조성물, 키트및 이의생산방법에관한것이다.
Abstract translation: 本发明涉及使用细菌细胞色素P450及其组合物从氟伐他汀生产代谢物的方法，更具体地说涉及含有来自氟伐他汀的细菌色素P450 BM3（CYP102A1）的5-羟基产物和6-羟基产物的组合物 ），CYP102A1的突变体和CYP102A1的突变体的嵌合体，试剂盒及其制备方法。
-
公开(公告)号：KR1020100063486A
公开(公告)日：2010-06-11
申请号：KR1020080122029
申请日：2008-12-03
Applicant: 전남대학교산학협력단
CPC classification number: C12P7/22 , C12N9/0071 , C12Y114/14001
Abstract: PURPOSE: A method for producing piceatannol is provided to selectively and massively produce expressive piceatannol from resveratrol. CONSTITUTION: A composition for catalytic reaction to produce piceatannol from resveratrol contains wild type CYP102A1 and/or CYP102A1 mutants. In the CYP102A1 mutant, 47th amino acid, ariginine to leucine; 64th amino acid, glutamic acid to glycine; 74th amino acid, alanine to glycine; 81th amino acid, phenylalanine to isoleucine; 86th amino acid, leucine to isoleucine; 87th amino acid, phenylalanine to valine; and 143th amino acid, glutamic acid to glycine.
Abstract translation: 目的：提供白藜芦醇的制备方法，以选择性和大规模地生产表达白皮ann醇。 构成：用于从白藜芦醇产生云杉醇的催化反应组合物含有野生型CYP102A1和/或CYP102A1突变体。 在CYP102A1突变体中，第47位氨基酸，亚氨基至亮氨酸; 第64位氨基酸，谷氨酸至甘氨酸; 第74位氨基酸，丙氨酸至甘氨酸; 第81位氨基酸，苯丙氨酸至异亮氨酸; 第86位氨基酸，亮氨酸至异亮氨酸; 第87位氨基酸，苯丙氨酸至缬氨酸; 和第143位氨基酸，谷氨酸至甘氨酸。
-
公开(公告)号：KR101774940B1
公开(公告)日：2017-09-20
申请号：KR1020150128399
申请日：2015-09-10
Applicant: 전남대학교산학협력단
CPC classification number: C12P19/46 , C12N9/0071 , C12Y114/14001
Abstract: 본발명은폴리데이틴의대사사산물중 아스트린진제조를위한조성물로서, 박테리아시토크롬 P450 효소인야생형 CYP102A1의환원효소영역과 CYP102A1 돌연변이체의헴영역을융합한 CYP102A1 키메라및 이의돌연변이체를촉매로이용하여폴레데이틴을산화시켜아스트린진을대량생산할수 있다.
-
公开(公告)号：KR101654313B1
公开(公告)日：2016-09-22
申请号：KR1020140134817
申请日：2014-10-07
Applicant: 전남대학교산학협력단
Abstract: 본발명은시토크롬 P450(CYP)의정제방법을제공한다. 본발명에따르면대표적인단백질정제방법인친화성-태그및 크로마토그래피등을이용하지않고, 혼합미셀을이용하여원-스텝방식으로시토크롬 P450을간편하고신속하게고효율및 고순도로정제할수 있다. 본발명은혼합미셀및 아비딘-비드를포함하는시토크롬 P450(CYP) 정제용조성물을제공한다.
-
20.发明授权
公开(公告)号：KR101613835B1
公开(公告)日：2016-04-21
申请号：KR1020140077026
申请日：2014-06-24
Applicant: 전남대학교산학협력단
IPC: A61K36/605
Abstract: 본발명은시토크롬 P450 효소로전환된오디추출물을포함하는염증성장질환의예방또는치료용약학조성물에관한것으로, 상세하게는시토크롬 P450 효소로전환된오디추출물로염증성장질환을완화시키고, 비정상적으로과도화된활성면역세포를조절하는약학조성물에관한것이다. 본발명을통해, P450 효소전환된오디추출물이대장조직내에점막의면역조절활성을유도함으로써, 염증성장질환의개선, 예방또는치료에유용하게활용될수 있을것으로기대된다.
-
-
-
-
-
-
-
-
-
Search Results
53
records
(took 0.019 seconds)
